Patents by Inventor Arash Raoufinia

Arash Raoufinia has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF ADMINISTERING AN ARIPIPRAZOLE INJECTABLE PREPARATION
    Publication number: 20230225962
    Abstract: The present disclosure is directed to the methods of treating a patient with schizophrenia or bipolar I disorder by administering to the patient an injectable preparation of aripiprazole, wherein the patient is administered the injectable preparation about once every two months.
    Type: Application
    Filed: March 15, 2023
    Publication date: July 20, 2023
    Inventors: Matthew Harlin, Xiaofeng WANG, Yanlin WANG, Arash RAOUFINIA
  • METHODS FOR DOSE INITIATION OF ARIPIPRAZOLE TREATMENTS
    Publication number: 20230129919
    Abstract: The present disclosure is directed to a method of dose initiation for an aripiprazole treatment to a patient in need thereof; the patient is administered two, separate 100 to 500 mg injections of an aripiprazole intramuscular (IM) depot formulation at separate gluteal and/or deltoid injection sites, and a single dose of oral aripiprazole. The administration occurs on a first day of the treatment.
    Type: Application
    Filed: April 1, 2021
    Publication date: April 27, 2023
    Inventors: Matthew HARLIN, Xiaofeng WANG, Yanlin WANG, Arash RAOUFINIA
  • METHOD OF PROVIDING ARIPIPRAZOLE TO PATIENTS HAVING IMPAIRED CYP2D6 OR CYP3A4 ENZYME FUNCTION
    Publication number: 20230071995
    Abstract: The disclosed embodiments relate to methods of initiating aripiprazole treatment in a patient who is a CYP2D6 poor metabolizer or a CYP3A4 poor metabolizer, or both.
    Type: Application
    Filed: April 28, 2022
    Publication date: March 9, 2023
    Inventor: Arash Raoufinia
  • Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
    Patent number: 11400087
    Abstract: The disclosed embodiments relate to methods of initiating aripiprazole treatment in a patient who is a CYP2D6 poor metabolizer or a CYP3A4 poor metabolizer, or both.
    Type: Grant
    Filed: June 23, 2021
    Date of Patent: August 2, 2022
    Assignee: Otsuka Pharmaceutical Co., Ltd.
    Inventor: Arash Raoufinia
  • Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
    Patent number: 11344547
    Abstract: The disclosed embodiments relate to methods of initiating aripiprazole treatment in a patient who is a CYP2D6 poor metabolizer or a CYP3A4 poor metabolizer, or both.
    Type: Grant
    Filed: September 9, 2021
    Date of Patent: May 31, 2022
    Assignee: Otsuka Pharmaceutical Co., Ltd.
    Inventor: Arash Raoufinia
  • METHODS OF ADMINISTERING AN ARIPIPRAZOLE INJECTABLE PREPARATION
    Publication number: 20220160621
    Abstract: The present disclosure is directed to the methods of treating a patient with schizophrenia or bipolar I disorder by administering to the patient an injectable preparation of aripiprazole, wherein the patient is administered the injectable preparation about once every two months.
    Type: Application
    Filed: April 1, 2021
    Publication date: May 26, 2022
    Inventors: Matthew Harlin, Xiaofeng WANG, Yanlin WANG, Arash RAOUFINIA
  • Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
    Patent number: 11273157
    Abstract: The disclosed embodiments relate to methods of initiating aripiprazole treatment in a patient who is a CYP2D6 poor metabolizer or a CYP3A4 poor metabolizer, or both.
    Type: Grant
    Filed: June 23, 2021
    Date of Patent: March 15, 2022
    Assignee: Otsuka Pharmaceutical Co., Ltd.
    Inventor: Arash Raoufinia
  • METHOD OF PROVIDING ARIPIPRAZOLE TO PATIENTS HAVING IMPAIRED CYP2D6 OR CYP3A4 ENZYME FUNCTION
    Publication number: 20220071992
    Abstract: The disclosed embodiments relate to methods of initiating aripiprazole treatment in a patient who is a CYP2D6 poor metabolizer or a CYP3A4 poor metabolizer, or both.
    Type: Application
    Filed: March 19, 2021
    Publication date: March 10, 2022
    Inventor: Arash Raoufinia
  • METHOD OF PROVIDING ARIPIPRAZOLE TO PATIENTS HAVING IMPAIRED CYP2D6 OR CYP3A4 ENZYME FUNCTION
    Publication number: 20220054482
    Abstract: The disclosed embodiments relate to methods of initiating aripiprazole treatment in a patient who is a CYP2D6 poor metabolizer or a CYP3A4 poor metabolizer, or both.
    Type: Application
    Filed: September 9, 2021
    Publication date: February 24, 2022
    Inventor: Arash Raoufinia
  • Once Daily Formulations Of Tetracyclines
    Publication number: 20220016041
    Abstract: Disclosed are once-daily formulations containing tetracyclines, especially doxycycline. Such formulations are useful, for instance, for the treatment of collagenase destructive enzyme-dependent diseases, such as periodontal disease and acne, and acute and chronic inflammatory disease states, such as rosacea and arthritis.
    Type: Application
    Filed: February 25, 2021
    Publication date: January 20, 2022
    Inventors: Rong-Kun Chang, Arash Raoufinia, Niraj Shah
  • Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
    Patent number: 11154553
    Abstract: The disclosed embodiments relate to methods of initiating aripiprazole treatment in a patient who is a CYP2D6 poor metabolizer or a CYP3A4 poor metabolizer, or both.
    Type: Grant
    Filed: June 23, 2021
    Date of Patent: October 26, 2021
    Assignee: Otsuka Pharmaceutical Co., Ltd.
    Inventor: Arash Raoufinia
  • METHOD OF PROVIDING ARIPIPRAZOLE TO PATIENTS HAVING IMPAIRED CYP2D6 OR CYP3A4 ENZYME FUNCTION
    Publication number: 20210315888
    Abstract: The disclosed embodiments relate to methods of initiating aripiprazole treatment in a patient who is a CYP2D6 poor metabolizer or a CYP3A4 poor metabolizer, or both.
    Type: Application
    Filed: June 23, 2021
    Publication date: October 14, 2021
    Inventor: Arash Raoufinia
  • METHOD OF PROVIDING ARIPIPRAZOLE TO PATIENTS HAVING IMPAIRED CYP2D6 OR CYP3A4 ENZYME FUNCTION
    Publication number: 20210308127
    Abstract: The disclosed embodiments relate to methods of initiating aripiprazole treatment in a patient who is a CYP2D6 poor metabolizer or a CYP3A4 poor metabolizer, or both.
    Type: Application
    Filed: June 23, 2021
    Publication date: October 7, 2021
    Inventor: Arash Raoufinia
  • Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
    Patent number: 10980803
    Abstract: The disclosed embodiments relate to methods of initiating aripiprazole treatment in a patient who is a CYP2D6 poor metabolizer or a CYP3A4 poor metabolizer, or both.
    Type: Grant
    Filed: December 11, 2019
    Date of Patent: April 20, 2021
    Assignee: Otsuka Pharmaceutical Co., Ltd.
    Inventor: Arash Raoufinia
  • METHOD OF PROVIDING ARIPIPRAZOLE TO PATIENTS HAVING IMPAIRED CYP2D6 OR CYP3A4 ENZYME FUNCTION
    Publication number: 20200360370
    Abstract: The disclosed embodiments relate to methods of initiating aripiprazole treatment in a patient who is a CYP2D6 poor metabolizer or a CYP3A4 poor metabolizer, or both.
    Type: Application
    Filed: December 11, 2019
    Publication date: November 19, 2020
    Applicant: Otsuka Pharmaceutical Co., Ltd.
    Inventor: Arash Raoufinia
  • Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
    Patent number: 10525057
    Abstract: The disclosed embodiments relate to methods of initiating aripiprazole treatment in a patient who is a CYP2D6 poor metabolizer or a CYP3A4 poor metabolizer, or both.
    Type: Grant
    Filed: September 24, 2013
    Date of Patent: January 7, 2020
    Assignee: Otsuka Pharmaceutical Co., Ltd.
    Inventor: Arash Raoufinia
  • Once Daily Formulations Of Tetracyclines
    Publication number: 20190125683
    Abstract: Disclosed are once-daily formulations containing tetracyclines, especially doxycycline. Such formulations are useful, for instance, for the treatment of collagenase destructive enzyme-dependent diseases, such as periodontal disease and acne, and acute and chronic inflammatory disease states, such as rosacea and arthritis.
    Type: Application
    Filed: October 26, 2018
    Publication date: May 2, 2019
    Inventors: Rong-Kun Chang, Arash Raoufinia, Niraj Shah
  • Once Daily Formulations of Tetracyclines
    Publication number: 20160113880
    Abstract: Disclosed are once-daily formulations containing tetracyclines, especially doxycycline. Such formulations are useful, for instance, for the treatment of collagenase destructive enzyme-dependent diseases, such as periodontal disease and acne, and acute and chronic inflammatory disease states, such as rosacea and arthritis.
    Type: Application
    Filed: June 2, 2015
    Publication date: April 28, 2016
    Inventors: Rong-Kun Chang, Arash Raoufinia, Niraj Shah
  • METHOD OF PROVIDING ARIPIPRAZOLE TO PATIENTS HAVING IMPAIRED CYP2D6 OR CYP3A4 ENZYME FUNCTION
    Publication number: 20150087654
    Abstract: The disclosed embodiments relate to methods of initiating aripiprazole treatment in a patient who is a CYP2D6 poor metabolizer or a CYP3A4 poor metabolizer, or both.
    Type: Application
    Filed: September 24, 2013
    Publication date: March 26, 2015
    Applicant: Otsuka Pharmaceutical Co., Ltd.
    Inventor: Arash Raoufinia
  • ONCE DAILY FORMULATIONS OF TETRACYCLINES
    Publication number: 20150057254
    Abstract: Disclosed are once-daily formulations containing tetracyclines, especially doxycycline. Such formulations are useful, for instance, for the treatment of collagenase destructive enzyme-dependent diseases, such as periodontal disease and acne, and acute and chronic inflammatory disease states, such as rosacea and arthritis.
    Type: Application
    Filed: March 19, 2014
    Publication date: February 26, 2015
    Applicant: Supernus Pharmaceuticals, Inc.
    Inventors: Rong-Kun Chang, Arash Raoufinia, Niraj Shah